Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Tommy1, I can respect your position on my post
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Craigbadon Aug 12, 2016 6:57pm
206 Views
Post# 25137819

RE:RE:RE:Tommy1, I can respect your position on my post

RE:RE:RE:Tommy1, I can respect your position on my postWell, if Donnatal gets pulled its probably a $0. Heck, if two drugs they just bought are worth half a billion less this quick, whos to say there won't be more. Debt to ebitda of 6.4 as a target? Really? Pretty much uninvestable for a fund and any more bumps its probably curtains.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities